September 11, 2019
MSCopilot®, the multiple sclerosis patient monitoring solution developed by Ad Scientiam, was clinically validated in a clinical trial involving several French hospitals.
The results are published in the European Journal of Neurology.
In Chicago, April 18-22, 2026, Ad Scientiam presented 4 scientific posters at the American Academy of Neurology, covering MSCopilot® in MS and ME&MG™ in generalized autoimmune myasthenia.
April 18, 2026
At the Cystic Fibrosis Scientific Days 2025, we presented MuCopilot®, our home monitoring tool based on digital biomarkers measured via smartphone.
March 9, 2026
In Dubai in December 2025, we presented MS-DETECT data on the correlation between MSCopilot® digital biomarkers and traditional clinical assessments.
December 5, 2025
Talk to our experts and discover how our solutions integrate into your practice or studies.
This site uses analytics cookies
We use Countly to measure audience and improve your experience. This data remains anonymous and is not shared with third parties.